Last $0.03 USD
Change Today -0.0032 / -9.71%
Volume 566.0K
As of 3:38 PM 03/3/15 All times are local (Market data is delayed by at least 15 minutes).

endexx corp (EDXC) Snapshot

Open
$0.03
Previous Close
$0.03
Day High
$0.03
Day Low
$0.03
52 Week High
03/19/14 - $0.36
52 Week Low
12/31/14 - $0.03
Market Cap
6.0M
Average Volume 10 Days
607.4K
EPS TTM
--
Shares Outstanding
199.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ENDEXX CORP (EDXC)

Related News

No related news articles were found.

endexx corp (EDXC) Related Businessweek News

No Related Businessweek News Found

endexx corp (EDXC) Details

ENDEXX Corp., through its subsidiaries, provides platforms for entrepreneurs. It offers m3Hub, a platform that manages patient concentric data and incorporates best patient privacy practices through verification, privacy, legal, and transparent controls, as well as legitimizes the entire transaction process on behalf of patients. The company also provides Project Canopy, a platform that provides coworkers and customers a virtual environment to work together as if they were sitting together in the same room. In addition, it operates as an integrator of renewable energy services for governments, electric utilities, communities, schools, churches, data centers, agriculture, irrigation districts, mining, and other remote area operations requiring dependable power systems, which include producing and providing renewable energy power; providing renewable energy power systems; providing services, including consulting, design and engineering, procurement, installation, monitoring, and maintenance; and offering financing options through power purchase agreements, project finance, and lease programs. ENDEXX Corp. was formerly known as Visual Board Books, Inc. The company is based in Cave Creek, Arizona.

endexx corp (EDXC) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

endexx corp (EDXC) Key Developments

Endexx Corporation Sign Digital Marketing Agreement with Voice Digital Services

Endexx Corporation announced that it has entered into a digital marketing agreement with Voice Digital Services to develop customized digital marketing strategies and create platforms for Endexx's marketing needs. The services will include cohesive branding of the entire M3Hub suite of technologies and products, including the E-commerce website for M3CBD line of hemp based CBD-rich oils, customized vaporizer kits and Cannsumable health products. The new website, CBDUnlimited.com, will be going live in March 2015. Voice Digital Services is initially developing the brand image, logos and presentation material for the Cannsumables division of Endexx and implementing market specific digital strategies including SEO, Social Media and others to generate product awareness, benefits and sales of CBD infused nutritional supplements to the multi-billion dollar consumer market for nutraceuticals and functional foods.

Endexx Corporation Announces Positive Results of Initial Diabetic Neuropathy Patient Study

Endexx Corporation announced that phase 1 of a diabetic neuropathy case study with the purpose of observing if M3CBD, a uniquely formulated CBD and CBD-A rich industrial hemp extract would mitigate or alleviate pain when inhaled through an electronic vaporizer, has been successfully completed. The case study was initiated in late November 2014 by Dr. Daniel Kiddy, as a voluntary patient study. Endexx provided its M3Vape starter kit to the study and food grade hemp oil extract from imported industrial hemp grown on a certified non-GMO eco-farm under strict organic practices. The batch used in the study was 100% natural and, free of all contaminants, pesticides, mold, bacteria and heavy metals. The hemp oil contained a rich blend of phytocannabinoids, including CBD, CBD-A, CBG, and CBC, and Citronellol, a powerful terpenoid, that together interact with cannabinoid receptors in what is known as the "entourage effect." Daniel Kiddy, DPM, compiled and documented preliminary results for phase 1 with the participation of thirteen volunteer patients, all of whom suffer from diabetic neuropathy. The participants administered a minimal dose of the oil through vaporizer inhalation three times a day. Results can be summarized as follows: Of the thirteen volunteers who participated in the trial, five did not follow the dosage protocol and are excluded from the results. Seven out of eight patients reported a decrease in pain level with improvements ranging from slight to as much as 75%, with one patient reporting being free of pain for the last 5 days of phase 1. One patient suffering from chronic migraine headaches reduced the use of prescribed pain medication (Sumatriptan) by 40%. Four patients stated improved sleep, feeling refreshed, energized or free of pain when waking up, while two patients experienced mood improvement, feeling happier and less depressed. One patient who experienced much improved sleep and reduced depression did not however experience any decrease in pain level. No patient reported adverse reactions. The choice of electronic vaporizer as a patient friendly delivery system was prompted by CBD's enhanced bioavailability and efficacy through inhalation. Cannabidiol has been shown in numerous human trials to be five times more bioavailable when inhaled than when taken orally. While these results are purely anecdotal and only provide very limited and incomplete information that is in no way meant to be conclusive, they nevertheless supply critical feedback for doctors and patients alike and are designed to increase public awareness of the potential therapeutic and wellness properties of high grade, naturally occurring hemp extracts that are rich in cannabidiol and other phytocannabinoids. The trial is ongoing and seeks to add to a body of existing data and to inspire more wide scale research and encourage advanced clinical trials on the specific role of certain cannabinoids, including CBD in particular, in exerting significant analgesic effects in various chronic pain conditions, without psychoactive or adverse effects.

Endexx Corporation Contributes to Diabetic Neuropathy Case Study

Endexx Corporation announced that it is providing its CBD (Cannabidiol) starter kit (M3Vape) to a voluntary patient study utilizing industrial hemp oil that is rich in CBD/CBDa, as an application to potentially alleviate symptoms arising from diabetic neuropathy. Thirteen diabetic patients suffering from neuropathy in Missouri began a 30 day voluntary study in late November under the oversight of Dr. Daniel Kiddy, DPM. Dr. The main objective for this short study is to simply see if pain is decreased or eliminated. The oil is naturally rich in both CBD and CBDa phytocannabinoids. The industrial hemp is grown on a certified eco-farm under organic farming practices. The oil is extracted utilizing critical CO2 extraction processes. The oil is tested both at the manufacturing site and in the United States at a certified lab. The product has no heavy metals, pesticides, or other contaminants and is tested using microbiological methods for determining mold and bacteria levels. Endexx is researching the higher quality sources of industrial hemp oil that achieves the following primary goals: The product must be safe. The product must be legal under federal law. The product must provide maximum bioavailability. The product must be beneficial to the patient/consumer. This study is not an official clinical trial. The study will provide general feedback from patients anecdotally, providing information to the doctors, patients and providers of the product. Public awareness of cannabis and industrial hemp products containing therapeutic and wellness properties has escalated over the past few years, yet education and research is limited. Understanding the benefits and the negatives of any supplement or nutraceutical is critical when determining the direction of a product's development and future use by the medical community and/or the general adult population.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EDXC:US $0.03 USD -0.0032

EDXC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for EDXC.
View Industry Companies
 

Industry Analysis

EDXC

Industry Average

Valuation EDXC Industry Range
No financial data is available for EDXC.
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ENDEXX CORP, please visit www.endexx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.